Enoxacin
Penetrex (enoxacin) is a small molecule pharmaceutical. Enoxacin was first approved as Penetrex on 1991-12-31. It is used to treat escherichia coli infections, gonorrhea, haemophilus infections, klebsiella infections, and proteus infections amongst others in the USA. It is known to target V-type proton ATPase subunit B, brain isoform.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
urogenital diseases | D000091642 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Enoxacin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PENETREX | Sanofi | N-019616 DISCN | 1991-12-31 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
penetrex(r) arthritis pain relief | unapproved drug other | 2022-06-20 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
gonorrhea | DOID_7551 | D006069 | A54 |
haemophilus infections | EFO_1001127 | D006192 | — |
klebsiella infections | EFO_1001353 | D007710 | — |
proteus infections | EFO_1001130 | D011512 | — |
pseudomonas infections | EFO_0001076 | D011552 | — |
staphylococcal infections | — | D013203 | A49.01 |
urinary tract infections | EFO_0003103 | D014552 | N39.0 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
39 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myelomonocytic leukemia chronic | D015477 | C93.1 | 2 | 3 | — | — | — | 5 | |
Hematologic neoplasms | D019337 | 2 | 1 | — | — | — | 2 | ||
Multiple myeloma | D009101 | C90.0 | 2 | 1 | — | — | — | 2 | |
Neoplasms | D009369 | C80 | 2 | 2 | — | — | — | 2 | |
Biphenotypic leukemia acute | D015456 | C95.0 | — | 1 | — | — | — | 1 | |
Glioma | D005910 | EFO_0000520 | 1 | 1 | — | — | — | 1 | |
Cholangiocarcinoma | D018281 | C22.1 | 1 | 1 | — | — | — | 1 | |
Chondrosarcoma | D002813 | 1 | 1 | — | — | — | 1 | ||
Leukemia | D007938 | C95 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 4 | — | — | — | — | 4 | ||
Hepatic insufficiency | D048550 | 2 | — | — | — | — | 2 | ||
Prostatic neoplasms | D011471 | C61 | 1 | — | — | — | — | 1 | |
Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | — | — | — | — | 1 |
Non-hodgkin lymphoma | D008228 | C85.9 | 1 | — | — | — | — | 1 | |
Primary myelofibrosis | D055728 | D47.4 | 1 | — | — | — | — | 1 | |
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 1 | — | — | — | — | 1 | |
B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | — | — | — | — | 1 |
Show 7 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | ENOXACIN |
INN | enoxacin |
Description | Enoxacin is a 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea. It has a role as an antibacterial drug and a DNA synthesis inhibitor. It is a monocarboxylic acid, an amino acid, a 1,8-naphthyridine derivative, a N-arylpiperazine, a quinolone antibiotic and a fluoroquinolone antibiotic. |
Classification | Small molecule |
Drug class | antibacterials (quinolone derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCn1cc(C(=O)O)c(=O)c2cc(F)c(N3CCNCC3)nc21 |
Identifiers
PDB | — |
CAS-ID | 74011-58-8 |
RxCUI | 3925 |
ChEMBL ID | CHEMBL826 |
ChEBI ID | 157175 |
PubChem CID | 3229 |
DrugBank | DB00467 |
UNII ID | 325OGW249P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ATP6V1B2
ATP6V1B2
Organism
Homo sapiens
Gene name
ATP6V1B2
Gene synonyms
ATP6B2, VPP3
NCBI Gene ID
Protein name
V-type proton ATPase subunit B, brain isoform
Protein synonyms
ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2, Endomembrane proton pump 58 kDa subunit, H+ transporting two-sector ATPase, HO57, testicular secretory protein Li 65, V-ATPase B2 subunit, V-ATPase subunit B 2, vacuolar H+-ATPase 56,000 subunit, Vacuolar proton pump subunit B 2
Uniprot ID
Mouse ortholog
Atp6v1b2 (11966)
V-type proton ATPase subunit B, brain isoform (Q3UAW7)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,936 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
2,268 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more